HEPATOPAC® User Group Meeting

BioIVT Team

Rob Taylor
Technical Sales Specialist, ADME-Tox Services, West Coast U.S.

Imola Juhasz, PhD 
Technical Sales Specialist ADME-Tox, Europe

Downloadable Resources

Learn more about our comprehensive products and services for ADME-Tox research.

• HEPATOPAC Brochure
• HEPATOMUNE Brochure
• HEPATOPAC Model: The Truth Revealed [BLOG]
• How Do You Silence A Gene Using siRNA In HEPATOPAC Co-Cultures? [BLOG]
• Selected HEPATOPAC and HEPATOMUNE Publications
  
  

HEPATOPAC  Technology
Long-term, Stable In Vitro Hepatic Model

HEPATOPAC Technology is used to create stable in vitro liver models that enable long-term hepatic metabolism and toxicity studies. HEPATOPAC cultures, formed using a proprietary patterning method, consist of hepatocyte “islands” surrounded with supportive stromal cells. This specialized architecture replicates the physiological microenvironment of the liver. Hepatocytes remain healthy and viable in the HEPATOPAC platform, and demonstrate physiologically-relevant transporter function and phase I and phase II metabolic activity for over four weeks

HEPATOPAC and HEPATOMUNE® Plates

HEPATOPAC and HEPATOMUNE plates are ready-to-use and available in a variety of sizes and formats.

Your order will contain everything needed to perform an assay including:

• HEPATOPAC or HEPATOMUNE cultures on high throughput 24-well or 96-well plates
• Maintenance and Application Media
• Instructions on handling and culturing plates

HEPATOPAC models show better in-vitro in-vivo correlations (IVIVC) than conventional hepatocyte models, especially for medium- and low-turnover compounds. HEPATOPAC plates remain viable for up to 4 weeks. HEPATOMUNE plates remain viable up to 10 days.

HEPATOPAC Plate Tips and Tricks

View the Presentations from This Year's Event

The Use of HEPATOPAC for Estimation of Fraction Metabolized by Cytochrome P450 (CYP) Enzymes
Speaker: Kenichi Umehera PhD, Senior Principal Scientist, Roche Pharmaceutical Research and Early Development

Generating a Primary Human Hepatocyte Isogenic Pair Using BioIVT’s HEPATOPAC
Speaker: Michelle Clasquin, PhD, Research Fellow and Lab Head in Internal Medicine Research Unit, Pfizer

Mimicking Fatty Liver Disease in HEPATOPAC: Examining Changes in Gene Expression and Outcomes of Gene Knockdown
Speaker: Karissa Cottier, PhD, Principal Scientist, BioIVT

View the 2021 Presentations